A novel blood test for tuberculosis prevention and treatment

South African Medical Journal

Volumn 107, Issue 1, 2017, Pages 4-5

  White, Richard G ^a   Sumner, Tom ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RNA; TRANSCRIPTOME; TUBERCULOSTATIC AGENT;

BLOOD; EARLY DIAGNOSIS; EARLY INTERVENTION; GENETICS; HUMAN; MASS SCREENING; POLYMERASE CHAIN REACTION; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; EARLY DIAGNOSIS; EARLY MEDICAL INTERVENTION; HUMANS; MASS SCREENING; POLYMERASE CHAIN REACTION; RNA; TRANSCRIPTOME; TUBERCULOSIS;

EID: 85021848179     PISSN: 02569574     EISSN: 20785135     Source Type: Journal    
DOI: 10.7196/SAMJ.2016.V107.I1.12230     Document Type: Editorial

References (14)

1. Statistics South Africa. Mortality and Causes of Death in South Africa, 2014: Findings from Death Notification. Pretoria: Statistics SA, 2015.
2. World Health Organization. Global Tuberculosis Report 2016:1-211. Geneva: WHO, 2016.
3. Mahomed H, Hughes EJ, Hawkridge T, et al. Comparison of mantoux skin test with three generations of a whole blood IFN-gamma assay for tuberculosis infection. Int J Tuberc Lung Dis 2006;10(3):310-316. http://dx.doi.org/10.1164/rccm.200608-1088OC
4. Houben RMGJ, Dodd PJ. The global burden of latent tuberculosis infection: A re-estimation using mathematical modelling. PLoS Med 2016;13(10):e1002152. http://dx.doi.org/10.1371/journal.pmed.1002152
5. Houben RMGJ, Menzies NA, Sumner T, et al. Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: A combined analysis of 11 mathematical models. Lancet Glob Health 2016;4(11):e806-815. http://dx.doi.org/10.1016/S2214-109X(16)30199-1
6. Malherbe ST, Shenai S, Ronacher K, et al. Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure. Nat Med 2016;22(10):1094-1100. http://dx.doi.org/10.1038/nm.4177
7. Esmail H, Lai RP, Lesosky M, et al. Characterization of progressive HIV-associated tuberculosis using 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission and computed tomography. Nat Med 2016;22(10):1090-1093. http://dx.doi.org/10.1038/nm.4161
8. Zak DE, Penn-Nicholson A, Scriba TJ, et al. A blood RNA signature for tuberculosis disease risk: A prospective cohort study. Lancet 2016;387(10035):2312-2322. http://dx.doi.org/10.1016/S0140-6736(15)01316-1
9. Foundation for Innovative New Diagnostics. Draft target product profile: Test for incipient tuberculosis. 2016. http://www.finddx.org/wp-content/uploads/2016/10/TPP-LTBIprogression-v82_20OCT2016.pdf (accessed 30 November 2016).
10. Petruccioli E, Scriba TJ, Petrone L, et al. Correlates of tuberculosis risk: Predictive biomarkers for progression to active tuberculosis. Eur Respir J 2016;pii:ERJ-01012-2016. http://dx.doi.org/10.1183/13993003.01012-2016
11. Zak D, Scriba TJ, Hatherill M, Penn-Nicholson A, Hanekom W. Predicting tuberculosis risk. Lancet 2016;388(10057):2233-2234. http://dx.doi.org/10.1016/S0140-6736(16)31653-1
12. The Correlate of Risk (COR) Targeted Intervention Study. http://www.clinicaltrials.gov.NCT02735590 (accessed 30 November 2016).
13. Lawn SD, Churchyard G. Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS 2009;4(4):325-333. http://dx.doi.org/10.1097/COH.0b013e32832c7d61
14. World Health Organization. Guidelines on the Management of Latent Tuberculosis Infection. Geneva: WHO, 2015.